Alzheimer's Disease Research Centers (P30 - Clinical Trials Not Allowed) | RFA AG 19 001

Opportunity Information: Apply for RFA AG 19 001

This opportunity is a National Institutes of Health (NIH) funding announcement from the National Institute on Aging (NIA) seeking applications to support Alzheimer’s Disease Research Centers (ADRCs) through the P30 center grant mechanism. The intent is to fund NIA-designated ADRCs as major hubs for research and scientific collaboration focused on Alzheimer’s disease and related dementias. These centers are expected to drive discovery about the biological nature of Alzheimer’s and related conditions, and to strengthen the field’s ability to improve prevention strategies, diagnostic approaches, care practices, and therapeutic development. A central theme is that ADRCs do not operate as isolated projects; they are meant to be coordinating centers that connect investigators, share infrastructure, and contribute resources that accelerate dementia-relevant research across institutions and NIH-supported networks.

The FOA emphasizes shared resources and coordinated research efforts. In practical terms, an ADRC funded under this announcement is expected to build and maintain core capabilities that multiple investigators can use, rather than functioning as a single-lab or single-project award. These shared resources typically include things like research infrastructure, standardized methods, data and biospecimen resource development, and administrative systems that make collaboration easier and more consistent. The announcement also highlights coordination with other NIH-funded programs and investigators, reinforcing that ADRCs are intended to strengthen national research capacity and harmonize efforts across the broader Alzheimer’s and dementia research ecosystem.

The activity uses a grant funding instrument and falls under the health funding activity category, with CFDA number 93.866. The opportunity is identified as RFA-AG-19-001. An important restriction is embedded directly in the title: “Clinical Trials Not Allowed.” That means applications should not propose clinical trials as part of the funded center activities under this FOA. The work supported is expected to advance research and infrastructure without running clinical trials within the scope of this specific P30 announcement.

Eligibility is broad and includes many types of U.S.-based applicants: state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (as long as they are not institutions of higher education, since those are listed separately); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly notes additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, it draws clear limits around foreign involvement: non-U.S. entities (foreign organizations and foreign institutions) are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, “foreign components” as defined by the NIH Grants Policy Statement are allowed, meaning certain internationally performed elements may be permissible if they meet NIH’s definition and requirements, even though the applicant organization itself must be U.S.-based.

In terms of funding scale, the listed award ceiling is $2,000,000, which provides a sense of the upper bound of support anticipated under this announcement. The announcement record shows an original closing date of June 4, 2018, and a creation date of January 25, 2018, indicating this was a time-bound funding opportunity from that period. Overall, the program is designed to support established or developing center-level infrastructure that can serve as a durable platform for Alzheimer’s and dementia research, with an emphasis on shared resources, collaboration, and coordinated national impact rather than running clinical trials within the grant’s scope.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alzheimer's Disease Research Centers (P30 - Clinical Trials Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
• This funding opportunity was created on 2018-01-25.
• Applicants must submit their applications by 2018-06-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AG 19 001

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: